These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27278095)

  • 1. Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
    Smits MM; Tonneijck L; Muskiet MH; Diamant M; Kramer MH; Cahen DL; van Raalte DH
    Diabet Med; 2017 Apr; 34(4):591-592. PubMed ID: 27278095
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
    Lando HM; Alattar M; Dua AP
    Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M; Bajaj M
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide once weekly in type 2 diabetes.
    Scheen AJ
    Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
    Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Horowitz M; Jones KL; Rayner CK
    Diab Vasc Dis Res; 2017 Jan; 14(1):59-63. PubMed ID: 27941058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 9. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 15. [Glucagon-like peptide 1 (GLP-1)].
    Parhofer KG
    MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is exenatide advancing the treatment of type 2 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jan; 7(1):109-12. PubMed ID: 16370928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
    Wajcberg E; Tavaria A
    Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide in combination therapy: small study, big market, and many unanswered questions.
    Malozowski S
    Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.